These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [In vitro and in vivo antibacterial activities of a new quinolone derivative, FD501].
    Author: Imamori K, Asaoka T, Matsumoto M, Maebashi K, Matsuda H, Tahara Y.
    Journal: Jpn J Antibiot; 1996 Mar; 49(3):264-72. PubMed ID: 8935122.
    Abstract:
    FD501 is a newly synthesized quinolone derivative with aminoazepine group at the C-7 position. The in vitro and in vivo antibacterial activities of FD501 were investigated comparing with those of norfloxacin, ofloxacin, ciprofloxacin and sparfloxacin. The in vitro antibacterial activities of FD501 against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, were equal to or higher than those of other quinolones. But its activities against Gram-negative bacteria were equal to or lower than those of other quinolones. Minimum inhibitory concentrations of FD501 against Gram-positive bacteria were similar to that of sparfloxacin. The bactericidal activity may be due to the inhibition of the DNA super-coiling activity of DNA gyrase. The area under the serum concentration-time curve of FD501 in rats following oral administration was larger than norfloxacin and ciprofloxacin and smaller than those of ofloxacin and sparfloxacin.
    [Abstract] [Full Text] [Related] [New Search]